207
Views
1
CrossRef citations to date
0
Altmetric
Suicide

The importance of suicide risk assessment in patients affected by neurofibromatosis

, , , , , , , ORCID Icon, & show all
Pages 350-355 | Received 10 Dec 2020, Accepted 19 Apr 2021, Published online: 16 Jul 2021

References

  • Ahmedani BK, Peterson EL, Hu Y, Rossom RC, Lynch F, Lu CY, Waitzfelder BE, Owen-Smith AA, Hubley S, Prabhakar D, et al. 2017. Major physical health conditions and risk of suicide. Am J Prev Med. 53(3):308–315.
  • American Psychiatric Association 2013. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Association.
  • Arnstein P, Caudill M, Mandle CL, Norris A, Beasley R. 1999. Self-efficacy as a mediator of the relationship between pain intensity, disability and depression in chronic pain patients. Pain. 80(3):483–491.
  • Beck AT, Steer RA, Kovacs M, Garrison B. 1985. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry. 1:559–563.
  • Beck AT, Ward C, Mendelson M, Mock J, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry. 4:561–571.
  • Belsher BE, Smolenski DJ, Pruitt LD, Bush NE, Beech EH, Workman DE, Morgan RL, Evatt DP, Tucker J, Skopp NA. 2019. Prediction models for suicide attempts and deaths: a systematic review and simulation. JAMA Psychiatry. 76(6):642–651.
  • Belvisi D, Berardelli I, Ferrazzano G, Costanzo M, Corigliano V, Fabbrini G, Berardelli A, Pompili M. 2019. The clinical correlates of suicidal ideation in Parkinson's disease. Parkinsonism Relat Disord. 63:54–59.
  • Berardelli I, Belvisi D, Corigliano V, Costanzo M, Innamorati M, Fabbrini G, Berardelli A, Pompili M. 2018. Suicidal ideation, perceived disability, hopelessness and affective temperaments in patients affected by Parkinson's disease. Int J Clin Pract.:e13287.doi: https://doi.org/10.1111/ijcp.13287.
  • Berardelli I, Belvisi D, Nardella A, Falcone G, Lamis DA, Fabbrini G, Berardelli A, Girardi P, Pompili M. 2019. Suicide in Parkinson's disease: a systematic review. CNS Neurol Disord Drug Targets. 18(6):466–477.
  • Berardelli I, Ferrazzano G, Belvisi D, Baione V, Fabbrini G, Innamorati M, Berardelli A, Pompili M. 2020. Suicidal ideation, hopelessness, and affective temperament in patients with blepharospasm. Int J Psychiatry Clin Pract.:1–6.  doi: https://doi.org/10.1080/13651501.2020.1790613.
  • Bergoug M, Doudeau M, Godin F, Mosrin C, Vallée B, Bénédetti H. 2020. Neurofibromin Structure, Functions and Regulation. Cells. 9(11):2365. Oct 27
  • Chung JH, Kim SH, Lee YW. 2016. Suicidal ideation and suicide attempts among asthma. Ann Gen Psychiatry. 15:35.
  • Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB. 2015. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clin Genet. 88(5):425–430.
  • Corke M, Mullin K, Angel-Scott H, Xia S, Large M. 2021. Meta-analysis of the strength of exploratory suicide prediction models; from clinicians to computers. BJPsych Open. 7(1):e26.
  • Denison E, Asenlöf P, Lindberg P. 2004. Self-efficacy, fear avoidance, and pain intensity as predictors of disability in subacute and chronic musculoskeletal pain patients in primary health care. Pain. 111(3):245–252.
  • Eskelinen M, Korhonen R, Selander T, Ollonen P. 2015. Suicidal ideation versus hopelessness/helplessness in healthy individuals and in patients with benign breast disease and breast cancer: a prospective case-control study in Finland. Anticancer Res. 35(6):3543–3551.
  • Eskelinen M, Korhonen R, Selander T, Ollonen P. 2017. Beck Depression Inventory as a predictor of long-term outcome among patients admitted to the breast cancer diagnosis unit: a 25-year cohort study in finland. AR. 37(2):819–824.
  • Eslami B, Kovacs AH, Moons P, Abbasi K, Jackson JL. 2017. Hopelessness among adults with congenital heart disease: cause for despair or hope? Int J Cardiol. 230:64–69.
  • Feinstein A. 2002. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 59(5):674–678.
  • Feinstein A, Pavisian B. 2017. Multiple sclerosis and suicide. Mult Scler. 23(7):923–927. Jun
  • Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. 2017. Neurofibromatosis type 1. Nat Rev Dis Primers. 3:17004Feb 23;
  • Innamorati M, Pompili M, De Filippis S, Gentili F, Erbuto D, Lester D, Tamburello A, Iacorossi G, Cuomo I, Dominici G, et al. 2009. The validation of the Italian Perceived Disability Scale (IPDS) in chronic daily headache sufferers. J Headache Pain. 10(1):21–26.
  • Innamorati M, Pompili M, Fiorillo M, Lala N, Negro A, Del Bono SD, Lester D, Girardi P, Martelletti P. 2013. Overattachment and perceived disability in chronic migraineurs. Clin Neurol Neurosurg. 115(7):954–958.
  • Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey Replication. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 289(23):3095–3105.
  • Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, Taruscio D. 2009. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 218(3):215–220.
  • Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, Nguyen R, Mautner VF, Plotkin SR. 2014. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet. 164 (6):1431–1437.
  • Middleton J, Tran Y, Craig A. 2007. Relationship between quality of life and self-efficacy in persons with spinal cord injuries. Arch Phys Med Rehabil. 88(12):1643–1648.
  • Murphy GE. 1998. Why women are less likely than men to commit suicide. Compr Psychiatry. 39(4):165–175.
  • Nicholson RA, Houle TT, Rhudy JL, Norton PJ. 2007. Psychological risk factors in headache. Headache. 47(3):413–426.
  • NIH 1988. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Neurofibromatosis. 1:172–178.
  • Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 140(18):1893–1898.
  • Pasquini M, Berardelli I, Cabra A, Maraone A, Matteucci G, Biondi M. 2011. Core depressive symptoms in depressed cancer OutpatientsB. Clin Pract Epidemiol Ment Health. 7:178–181.
  • Pompili M. 2018. The increase of suicide rates: the need for a paradigm shift. Lancet. 392(10146):474–475.
  • Pompili M. 2019. Epidemiology of suicide: from population to single cases. Epidemiol Psychiatr Sci. 29:e68.
  • Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, Amore M, Girardi P. 2012. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 73(6):411–417.
  • Pompili M, Tatarelli R, Rogers JR, Lester D. 2007. The hopelessness scale: a factor analysis. Psychol Rep. 100(2):375–378.
  • Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, et al. 2011. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 168(12):1266–1277.
  • Riccardi VM. 1981. Von Recklinghausen neurofibromatosis. N Engl J Med. 305(27):1617–1627.
  • Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, Rasoulpoor S, Khaledi-Paveh B. 2020. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health. 16(1):57.
  • Tian N, Cui W, Zack M, Kobau R, Fowler KA, Hesdorffer DC. 2016. Suicide among people with epilepsy: a population-based analysis of data from the U.S. National Violent Death Reporting System, 17 States, 2003-2011. Epilepsy Behav. 61:210–217.
  • Tsigebrhan R, Hanlon C, Medhin G, Fekadu A. 2017. Help seeking and suicidality among people with epilepsy in a rural low income country setting: cross-sectional survey. Int J Ment Health Syst. 11:44.
  • Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR. 2012. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 14(12):977–982.
  • Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. 2001. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol. 137(11):1421–1425.
  • Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. 2003. Visibility of neurofibromatosis 1 and psychiatric morbidity. Arch Dermatol. 139(1):103–104.
  • Zöller ME, Rembeck B. 1999. A psychiatric 12-year follow-up of adult patients with neurofibromatosis type 1. J Psychiatr Res. 33(1):63–68.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.